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ABSTRACT
Recent insights into the pathological role of Nucleotide P2Y2 receptor suggest P2Y2R
involvement in high fat diet-induced obesity and potentiates insulin resistance. However, these
recent insights do not demonstrate how P2Y2R modulates glucose homeostasis under
physiological conditions. Further, it remains unknown how sex biological factors influence
P2Y2R receptor signaling in the regulation of glucose homeostasis. The research objective for the
present study is to elucidate the novel roles of P2Y2 in fasting blood glucose and glucose
tolerance (basal insulin sensitivity) under resting conditions in males and females. We expected
that under physiological conditions P2Y2R signaling does not contribute to maintaining glucose
homeostasis; we did not expect differences in fasting blood glucose and glucose tolerance
between the wild type and the P2Y2R-/- mice. We further hypothesized that sex differences in
fasting blood glucose and glucose tolerance would be present in wild type and P2Y2R-/- mice. We
assessed fasting blood glucose (FBG) and glucose tolerance test in C57BL/6 (wild type) and
P2Y2R-/- mice. Mice fasted for 5 hours, and blood was obtained from the tail to assess glucose
levels using a glucometer. Mice received 2 g/kg body weight intraperitoneal (IP) injection of
20% dextrose. Glucose levels were measured at time 0 (fasting), then over 90 minutes after IP
injection. In the current study, no significant difference was observed in FBG between wild type
and P2Y2R-/- in males and females. However, it was observed that P2Y2R-/- males had impaired
glucose tolerance relative to wild type, while females exhibited no differences. Sex differences in
wild type, but not P2Y2R-/- mice in FBG were observed. However, sex differences in glucose
tolerance were observed in WT and P2Y2R-/- mice, demonstrating females had improved glucose
tolerance relative to males. The findings demonstrate P2Y2R in males contributes to
physiological control of glucose homeostasis during a glucose tolerance test. Further, only WT
mice demonstrated sex-specific differences in FBG, suggesting a sex-specific role for P2Y2R
under fasting conditions.

KEYWORDS: glucose homeostasis, glucose tolerance, insulin resistance, nucleotide signaling,
extracellular nucleotides, inflammation, inflammation-induced insulin resistance, P2Y2 Receptor
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INTRODUCTION

Maintaining whole-body glucose homeostasis (euglycemia) requires coordination and
communication between multiple organ systems. The regulatory system consists of central
control through neural activity and peripheral control through activities of peripheral organs,
including the pancreas, liver, skeletal muscle, and adipose tissue, through the release of
hormones. Importantly, peripheral control is key for the insulin-dependent glucose clearance
from circulation. If control is disrupted, we become at risk for the development of chronic
hyperglycemia and insulin resistance which can lead to disease such as Type 2 Diabetes (T2D).
Emerging evidence reveals that proinflammatory mediators interrupt insulin signaling in
peripheral tissue, which leads to insulin resistance.
Nucleotide signaling regulates physiological and pathophysiological states, specifically
the inflammatory response. Intracellular nucleotides (ATP, ADP, UTP, UDP) released into the
extracellular space activate nucleotide signaling by nucleotide receptors. Recently, in vitro, and
in vivo studies have demonstrated that nucleotide receptor P2Y2R is involved in
pathophysiological situations that promote insulin resistance (1, 73, 93, 101, 153). In this study,
we set out to better define the physiological role of P2Y2R in regulating glucose homeostasis by
answering the question: What physiological role does P2Y2R have in fasting blood glucose and
whole-body glucose tolerance in vivo?
Sex is an important biological variable in maintaining glucose homeostasis through
different regulatory mechanisms. Over the past several years, it has been realized the importance
of conducting studies that include female and male subjects in both animal and human studies.
Animal studies have largely used male animals due to misconceptions of how female
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reproductive hormones and the estrus cycle may influence the results or make study design more
difficult. However, we know that sexual dimorphisms in health and disease exist and must be
accounted for. In the current study we strive to account for sexual dimorphism by using both
female and male mice.
Little is known of P2Y2R signaling and associated regulation of glucose homeostasis
between the two sexes. Sex-specific differences in blood glucose tolerance and insulin sensitivity
have been established previously in human and animal studies (89, 96, 107, 129, 134). Although
sex hormones are an important factor responsible for these differences, genes on X and Y
chromosomes and environmental factors also contribute to sex-related differences in
cardiovascular, immune, and metabolic system (41, 77, 92). In this study, sex-specific
differences in P2Y2R-mediated regulation of glucose homeostasis were assessed.
Our objective for the present study is to elucidate the novel roles of P2Y2 in fasting blood
glucose and glucose tolerance (basal insulin sensitivity) under resting conditions in males and
females. We expected that under physiological conditions P2Y2R signaling does not contribute
to maintaining glucose homeostasis no differences in fasting blood glucose and glucose tolerance
between the wild type and the P2Y2R-/- mice. We further hypothesized that sex differences in
fasting blood glucose and glucose tolerance would be present in wild type and P2Y2R-/- mice.

Pancreatic Regulation of Blood Glucose
Pancreatic Hormones: Insulin and Glucagon. Pancreatic regulation of glucose
homeostasis is mediated by endocrine hormones such as insulin and glucagon. The secretion of
these hormones occurs due to the fluctuations in circulating blood glucose concentrations during
the absorptive (fed conditions) and postabsorptive (fasting fasting) state (Fig. 1). The endocrine
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pancreas releases insulin and “counter-regulatory” hormone glucagon; these hormones are
responsible for maintaining glucose homeostasis (Fig. 1) (57, 75, 90, 121). Insulin secretion
results from increased blood glucose concentrations (35, 52, 121). Insulin stimulates clearance of
glucose, reducing blood glucose. Contrarily, glucagon stimulates endogenous hepatic glucose
production, raising blood glucose. When glucose levels decrease between meals glucagon is
released from the pancreas to maintain the normal blood glucose level through a negative
feedback mechanism (76, 121).The secretion of insulin and activation of insulin receptor
signaling are the most important components in maintaining physiological glucose homeostasis.

↑ blood glucose concentrations

Absorptive state: fed conditions

↑ blood glucose

Endogenous glucose
synthesis

Maintained between 60 and
100 mg/dl
Glycogen
formation

↓ blood glucose

Blood glucose
concentration ↓

Post-absorptive state: fasting
conditions
Glucose uptake by GLUT4, stored
as glycogen (SKM) or
triglycerides (adipose)

Fig. 1. Maintaining glucose homeostasis is critical for human life to be sustained. The key
regulatory system in glucose homeostasis is composed of the pancreas, skeletal muscle,
liver, adipose tissue, and pancreatic hormones insulin and glucagon. Regulation occurs
under two different states to maintain circulating glucose between 60 and 100 mg/dl. The
absorptive state (orange arrows) occurs after eating and is characterized by increase blood
glucose levels and the distribution of nutrients. Insulin is secreted in response to increased
blood glucose levels to facilitate insulin dependent glucose update into the skeletal muscle
and adipose tissue and inhibited endogenous glucose production in the liver. The postabsorptive state (purple arrows) occurs during fasting conditions. Glucose levels start to
drop, and the body needs to find a way to provide energy to tissue. Glucagon is released
from the pancreas to stimulate endogenous glucose production in the liver, thus provide
energy and nutrients to the body between meals.
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The endocrine portion of the pancreas is composed of clusters of different cell types
referred to as the islet of Langerhans. Islets are composed of α, β, δ, ɛ, and γ cells (35). Alpha
cells release glucagon, β cells release insulin, δ cells release somatostatin, ɛ cells produce
ghrelin, and γ cells produce pancreatic polypeptide (35, 121). The fluctuations of blood glucose
concentrations throughout the day are sensed by endocrine cells in the islet of Langerhans (72).
As a result, the appropriate hormone is released. The islets are highly vascularized with
fenestrated capillaries. These characteristics of the vasculature facilitate glucose delivery and
sensing by the islet cells (72).
Glucose-Stimulated Insulin Secretion. Under fed conditions, such as eating a meal,
increased circulating glucose triggers insulin secretion from β cells. Glucose is taken up by β
cells through glucose transporters, enters glycolysis following phosphorylation by glucokinase,
and produces glucose-6 phosphate (G6P). From G6P, pyruvate is produced and enters the TCA
cycle leading to an increase in intracellular ATP and raising the ATP/ADP ratio in the β cells
(79). Increase in ATP/ADP ratio by high glucose concentration in the β cells leads to closure of
the ATP-sensitive K+ channels (KATP channels), causing membrane depolarization. As a result,
voltage gated Ca2+ channels open and allows the influx of calcium. Raised intracellular calcium
levels stimulate insulin secretion into the bloodstream (52, 79).
Insulin enters circulation and promotes glucose uptake in peripheral tissues to reduce
blood glucose levels, which is a key mechanism to maintain glucose homeostasis. Physiological
insulin secretion from β cells is considered biphasic (64). The first phase occurs within two
minutes of meal ingestion and sustained for 15-30 minutes, promoting glucose utilization in the
periphery. Following this, the second phase of insulin secretion occurs and is sustained until
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normal glucose levels are reached. Insulin secretion during the second phase can last for several
hours (64).
Insulin in circulation enters the interstitial space and binds to insulin receptors located in
the peripheral tissue. The main peripheral tissues responsible for glucose uptake in response to
insulin stimulation include skeletal muscle, adipose tissue, and the liver. Insulin receptor
activation in the liver also inhibits endogenous glucose production (37). The increase of
circulating glucose triggers insulin, the key molecule responsible for the uptake of glucose into
the tissue.
Insulin Receptor Signaling. The insulin receptor is a member of the receptor tyrosine
kinase family and is the key receptor responsible for glucose uptake in the skeletal muscle and
adipose tissue. This well charazitered mechanism is demonstrated in Fig. 2. Insulin binds to the
receptor’s extracellular domain, causing autophosphorylation of the tyrosine kinase on the
intracellular domains. The insulin receptor substrate (IRS-1/2) is recruited to the site of the

PIP3

PIP2

GLUT4

PI3K
Insulin
Receptor

PDK

IRS-1/2
Try

AKT

Fig. 2. Insulin receptor signaling transduction during the absorptive state. Insulin binds to the
insulin receptor on the skeletal muscle cells or WAT and activates the receptor. This leads to
tyrosine phosphorylation of IRS-1/2. IRS-1/2 associates with PI3K. PI3K synthesizes PIP3
from PIP2. PIP3 stimulates the recruitment of PDK and AKT to the plasma membrane. PDK
phosphorylates AKT, leading to AKT activation. AKT associates with GLUT4 containing
vesicles, stimulating the translocation of GLUT4 to the plasma membrane. GLUT4 facilitates
glucose uptake into the cell.
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insulin receptor following receptor activation and becomes phosphorylated. Once
phosphorylated, IRS isoforms 1 and 2 (IRS-1/2) may activate two different pathways: One
pathway is the MAP-K signaling pathway that promotes cell growth and proliferation (54, 108,
136). The other is the phosphoinositide 3-kinases pathway (PI3K) (Fig. 2 ) which promotes
insulin-stimulated glucose uptake into the peripheral tissue that requires insulin for glucose
uptake (15) and nitric oxide (NO) production (108, 136).
For insulin stimulate glucose uptake, the PI3K pathway is activated (Fig. 2). IRS-1/2
binds with the PI3K and phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2), and
generates phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 activates protein 3phosphoinositide-dependent protein kinase-1 (PDK-1) which subsequently activates AKT, also
known as protein kinase B (PKB). AKT binds to vesicles containing glucose transporters,
leading to the translocation glucose transporters to the plasma membrane. Through the glucose
transporters, glucose is taken into skeletal muscle and adipose tissue, thus decreasing plasma
glucose concentrations (15, 37).
Class I Facilitative Glucose Transporters. Glucose transporters (GLUTs) 1-4 are well
characterized and classified as Class I Facilitative Glucose Transporters. They are involved in
glucose sensing, import and export; and in signal transduction to maintain glucose homeostasis.
It should be noted that two additional classes of GLUTs exist: Class II and Class III Facilitative
Glucose Transporters. For the context of this thesis, Class I Facilitative Glucose Transporters are
highlighted (104). GLUT2 is a sensor of glucose concentrations and an importer of glucose in
pancreatic β cells. GLUT2 is also expressed on hepatocytes and facilitates glucose transport and
sensing (104, 139, 140). The brain requires constant energy and expresses GLUT3. GLUT3 has a
high affinity for glucose and allows for the constant influx of glucose to maintain energy. Like
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GLUT3, GLUT1 continuously imports glucose into tissue that requires constant energy, such as
erythrocytes. GLUT4 is prominently expressed in skeletal muscle and adipose tissue to take up
glucose in response to insulin receptor signaling (65, 140).

Regulation of Blood Glucose by the Liver, Skeletal Muscle, and Adipose Tissue.
Mechanisms of regulating glucose homeostasis by peripheral tissues depends on the
metabolic state. Under the absorptive state (fed conditions), when a meal is consumed, glucose is
produced from the digestion of complex carbohydrates. Glucose and other monosaccharides are
absorbed across the mucosal wall of the small intestines, to enter circulation in the blood.
Glucose is cleared in the absorptive state by insulin dependent glucose uptake in the skeletal
muscle, liver, and white adipose tissue. Conversely, during the post-absorptive state between
meals, while sleeping, and during fasting blood glucose levels fall. Due to the energy demands of
the tissue, glucose is produced endogenously to provide energy. The post-absorptive state is
governed by glucagon and its actions on the liver. Glucagon acts on the liver to stimulate the
breakdown of stored glycogen in the liver or to utilize non-carbohydrate precursor molecules to
produce glucose. This is imperative to the maintenance of steady-state glucose supply for energy
by utilization of glucose stores, triglycerides, and amino acids (133, 151).
Hepatic Regulation of Blood Glucose. Hepatic regulation of blood glucose occurs
during the absorptive state when insulin inhibits endogenous glucose production and promotes
glucose storage in the form of glycogen (59). Suppression of endogenous glucose production by
insulin prevents hyperglycemia, which can be detrimental to the body and contribute to Type 2
Diabetes. During the absorptive state glucose taken into the liver undergoes the processes of
glycolysis and glycogenesis. Under these conditions glycolysis converts glucose to pyruvate to
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generate energy. Insulin mediated AKT signaling stimulates glycogenesis in the absorptive state.
During glycogenesis, excess glucose molecules are added together to create glycogen as stored
energy (121). Between meals glycogen is utilized to provide energy to the body.
In the post-absorptive state, endogenous glucose production in the liver is regulated by
glucagon. Glucagon’s role in hepatic glucose regulation is to stimulate endogenous glucose
production through two pathways, glycogenolysis and gluconeogenesis and inhibiting
glycogenesis (75). Glucagon binds to G protein-coupled receptors located on hepatocytes,
activating metabolic pathways to produce glucose through adenylyl cyclase/ PKA (4, 9, 59). In
post-absorptive state, glycogen is broken down into glucose by Glycogenolysis. Glycogenolysis
is activated under short-term fasting condition. Here, glycogen stored from meals is broken down
to produce glucose. If glycogen stores are depleted (long-term fasting or starvation), noncarbohydrate precursors are utilized to generate glucose. During starvation, gluconeogenesis is
activated so that non-carbohydrates such as amino acids, fatty acids, and glycerol are used to
produce glucose.
Skeletal Muscle in Blood Glucose Regulation. The skeletal muscle is considered the
predominant insulin-sensitive tissue in the body, contributing 70-80% of insulin-dependent
glucose disposal (5, 78). It is well evidenced in the skeletal muscle that exogenous glucose
uptake requires three important steps: 1) the delivery of glucose from circulation to the
interstitial space; 2) insulin-stimulated translocation of GLUT4; 3) the irreversible
phosphorylation of glucose by hexokinase (148). Once glucose is phosphorylated it may enter
glycolysis or glycogenesis. Glucose designated for the glycolytic pathway is utilized for ATP
synthesis, allowing muscle contraction and movement. Glucose entering glycogenesis are added
together to produce glycogen for energy reserves. Unlike stored glycogen in the liver, glycogen
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stored in the skeletal muscle cannot be converted back to glucose when blood glucose levels
drop (94). When the liver has run out of stored glycogen and hepatic gluconeogenesis starts
during starvation, skeletal muscle generates non-carbohydrate precursors that are delivered to the
liver and then converted into glucose.
Adipose Tissue in the Regulation of Glucose Homeostasis. White adipose tissue is
responsible for maintaining glucose homeostasis through the storage of excess nutrients and
secretion of hormones. Excess glucose is taken up by the adipose tissue and converted to
glycogen and triglycerides through lipogenesis (122). Lipogenesis is hormonally regulated by
insulin, leading to the activation of metabolic pathways that promotes nutrient storage in adipose
tissue. Contrarily, when blood glucose levels drop during fasting or starvation, triglycerides are
metabolized into free fatty acids (FFAs) and glycerol and released into blood circulation. These
two molecules are precursor molecules for endogenous glucose production in the liver when
glycogen stores are depleted FFAs and glycerol are released into blood circulation and are
brought to the liver (91).

Disruption of Glucose Homeostasis
Insulin resistance occurs when the peripheral tissue no longer effectively responds to
insulin, leading to impaired glucose uptake. This leads to hyperinsulinemia and hyperglycemia.
Insulin resistance can occur in several pathophysiological conditions, including cardiovascular
disease, pre-diabetes, diabetes mellitus, obesity, and metabolic syndrome (103). Even infection
and inflammatory diseases share this common trait of insulin resistance.
Development of Type 2 Diabetes. Diabetes is characterized by above-normal blood
glucose concentrations. Diabetes can be broken down into three main diseases: Type 2 Diabetes

9

(T2D), Type 1 Diabetes (T1D), and gestational diabetes. According to the Center of Disease
Control (CDC), 34.2 million people across different ages had diabetes as of 2020, encompassing
10.5% of the population of the United States. Of this population, 26.9 million were diagnosed
while 7.3 million adults are undiagnosed. Undiagnosed individuals were determined by fasting
blood glucose levels and glycated hemoglobin, A1c (29). Additionally, 88 million adults in 2020
were diagnosed with prediabetes, encompassing 34.5% of the population of the United States
(29). While prediabetes is a condition preceding diabetes where glucose levels are higher than
normal but, in the range to be diagnosed with diabetes.
If glucose homeostasis is disrupted, the development of disease may occur. Prolonged
disturbances in glucose homeostasis are associated with T2D. Detection of these disturbances are
key, as excessive blood glucose levels are damaging to the body. To assess disturbances two
parameters and their diagnostic criteria (Table 1) are used regularly for patients suspected of
having prediabetes and T2D: Fasting blood glucose and oral glucose tolerance test (OGTT), a
commonly used test for diabetes in humans.
To assess fasting blood glucose (FBG) levels an individual must fast overnight and then
come into the clinic to have their blood glucose levels read by having their blood drawn. Fasting
blood glucose levels above 100 mg/dl may indicate an abnormality in glucose regulation in the
post-absorptive state. Such as abnormal endogenous glucose production, insulin resistance, and
impaired insulin secretion. The second measurement is derived from the OGTT. Individuals
undergo an overnight fast, go into the clinic to have their FBG read, ingest a drink containing 75
grams of sugar, and have BG levels two hours after. This test is used to evaluate the body’s
response to exogenous glucose during the absorptive state by comparing the FBG to the blood
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glucose levels obtained after the two hours. The increase in blood glucose from “normal” 120
mg/dl after 2 hours suggest a decrease in glucose metabolism such as insulin resistance.
The results derived from both these test aid in the diagnose of prediabetes and T2D
(Table 1). For example, prediabetes can be characterized clinically as impaired fasting glucose
(IFG) and impaired glucose tolerance (IGT). IFG indicates increase in endogenous glucose
production in the liver, potentially due to liver insulin resistance (38, 102). In insulin resistance,
the peripheral tissue’s sensitivity to insulin is decreased, potentially resulting in IGT. IGT
indicates a decrease of glucose uptake in the skeletal muscle and adipose tissue (38, 102).

Table 1. Diagnostic blood glucose values used to identify prediabetes and T2D
euglycemia
prediabetes
type 2 diabetes
(normal glucose
(impaired glucose
tolerance)
tolerance)
fasting glucose
less than 100
100 - 125 mg/dl
above 126 mg/dl
mg/dl
2 Hours Post
less than 140
140 – 200 mg/dl
above 200 mg/dl
OGTT Glucose
mg/dl
*Values described are collected from the American Diabetes Association

When insulin resistance develops, the pancreas needs to work “harder” to maintain
euglycemia and does this by secreting excess insulin to overcome increasing blood glucose
levels (38, 138). This increase in insulin secretion, referred to as hyperinsulinemia, can only
combat increasing concentrations of blood glucose and insulin resistance for a given period in
most patients. Eventually, β cells may no longer secrete more insulin to match the increasing
demands and lead to β-cell dysfunction (Fig. 3). As a result, hyperglycemia appears and insulin
secretion decreases. Insulin resistance can be caused by alterations at any step of the signaling
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cascade: the insulin receptor, downstream signaling molecules, glucose transporters, and/or
intracellular utilization of glucose (38).
Insulin resistance can be caused by alterations at any step of the signaling cascade: the
insulin receptor, downstream signaling molecules, glucose transporters, and/or intracellular
utilization of glucose (38). Insulin resistance may also be caused by impaired delivery of insulin
and glucose to skeletal muscle or adipose tissue from circulation. Inflammation, for example is a
cause of insulin resistance by disrupting insulin receptor signaling and impairing cardiovascular
delivery of glucose and insulin to the peripheral tissue. The effects of inflammation on glucose
homeostasis have been extensively studied and may occur under acute and chronic inflammatory
situations.

Development of Type 2 Diabetes
Hyperglycemia

Hyperinsulinemia
• ↓ Decrease
peripheral
insulin
sensitivity
Insulin
resistance

• β cells can no longer
increase insulin
secretion to maintain
glycemic levels.

• β cell ↑ of insulin
secretion
• Maintain
euglycemia

• Blood glucose
levels rise as β
cell dysfunction
increases

β cell
dysfunction

Fig. 3. Development of Type 2 Diabetes. Several disturbances occur leading to T2D. Early
in the development of T2D is insulin resistance. Insulin resistance in the peripheral tissue
such as skeletal muscle, adipose tissue, and liver occurs due to genetics, aging, obesity,
thus the tissue becomes less responsive to insulin in the absorptive state, making it harder
for the body to clear glucose from circulation. Due to the decreased insulin sensitivity, the
pancreatic β cells pump out more insulin to overcome the insulin insensitivity, defined as
hyperinsulinemia. Overtime βcell dysfunction occurs. The overcompensating β are worn
out and can no longer secrete excess insulin – this is the defining point in characterizing
T2D. Hyperglycemia develops due to the increasing β cell dysfunction.
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Chronic Inflammation in the Disruption of Glucose Homeostasis. Chronic, low-grade
inflammation is a hallmark of T2D and obesity. Patients with T2D have increased levels of
circulating cytokines such as interleukin one beta (Il-1β), tumor necrosis factor alpha (TNF-α),
interleukin six (Il-6), and C-reactive protein (CRP) have been considered as therapeutic targets to
treat T2D (31, 42, 58, 132). Pro-inflammatory cytokine TNF-alpha was the first inflammatory
mediator discovered to potentiate insulin resistance in the adipose tissue. Since then, it is well
established that a pro-inflammatory environment evokes local and systemic insulin resistance
(31, 50, 58). Increase in production of pro-inflammatory cytokines, chemokines, ATP/UTP, and
activation of intracellular signaling molecules such as kinases c-Jun N-terminal kinase (JNK) and
IĸKB kinase is attributed to the inhibition of insulin effects on glucose uptake. Overnutrition is a
suspected cause of the development of inflammation in T2D and obesity.
Overnutrition, namely high-fat diet (HFD), induces stress in the tissue metabolism,
stimulating the production of inflammatory mediators (45). Experimental models of high-fat
diet-induced obesity in mice have been used to characterize the connection between
inflammation and metabolic diseases. HFD feeding alters the immune responses in tissues such
as the pancreas, liver, skeletal muscle, and adipose tissue, and enable the development of insulin
resistance through the production of pro-inflammatory pathways and cytokines (42). The
development of this pro-inflammatory state under HFD feeding is in part, mediated by nucleotide
receptor P2Y2R.
Acute Inflammation and the Disruption of Glucose Homeostasis. Glucose
homeostasis is disrupted independent of a history of diabetes and pre-diabetes during critical
illness, such as severe infection accompanied by the production of pro-inflammatory mediators
like chronic inflammation and/or impaired cardiovascular function (6, 27, 42, 55, 87, 130,
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141).Clinically, the role of insulin resistance and hyperglycemia in stress, sepsis (LPS-induced
inflammation), and severe illness is of great importance. LPS-induced inflammation
in experimental models has been used to elucidate the cause-effect relationship between the proinflammatory mediators and impaired glucose homeostasis (110). During infection, insulin
resistance is facilitated by interruptions in the insulin signaling cascade by pro-inflammatory
molecules. Moreover, impaired cardiovascular function disrupts delivery of insulin and glucose
from circulation to the peripheral tissue (63, 95, 109).
Bacterial infections have the potential to become severe and illicit a strong proinflammatory response, septic shock, and organ failure (40, 125). Gram-negative bacteria contain
an endotoxin on their outer membrane called lipopolysaccharides (LPS). When LPS is released
from the bacterial wall it binds to toll-like receptor 4 (TLR4), on the plasma membrane of
immune cells to facilitate the activation of the innate immune system (111). Activation of TLR4
leads to the transcription of inflammatory cytokines by inducing NF-κB translocation to the
nucleus. The inflammatory cytokines and molecules include TNF-α, Il-6, Il-1β, Il-10, type 1
interferons, nitric oxide (NO), reactive oxygen species (ROS), and leads to the release of
extracellular nucleotides from the immune cells (55, 90, 132, 150). The ramifications of the proinflammatory response and increase in pro-inflammatory mediators can lead to insulin resistance
in the peripheral tissue by impeding insulin receptor signaling and glucose uptake.
Activation of cytokine receptors, TLR4, and nucleotide receptors by extracellular
nucleotides interrupts insulin signaling by inhibiting activation of the PI3K-AKT pathway.
During normal insulin signaling, insulin binds to the insulin receptor leading to the
phosphorylation of a tyrosine on IRS-1/2 and leads to AKT activation and GLUT4 translocation
to the membrane to bring glucose into the cell. During the pro-inflammatory state, a serine on the

14

IRS-1/2 molecule is phosphorylated instead of tyrosine, or phosphorylation of AKT is inhibited.
This impedes GLUT4 translocation to the cell membrane (115, 116).
Hyperinsulinemic-euglycemic clamp studies demonstrated impaired muscle glucose
uptake when treated with high doses of LPS. In this study, alterations to the insulin signaling
pathway were not observed, but impaired cardiovascular function was proposed to be responsible
for the insulin resistance. It is suspected that insulin and glucose delivery from circulation to the
interstitial space might be disrupted under these conditions (99). In another study, skeletal
muscle microvascular alterations were observed using intra-vital microscopy using insulin with a
fluorescent tag, showing alterations in microvascular flow and decrease of insulin accumulation
in the interstitial space in mice challenged with LPS (95). One reason for cardiovascular
challenges might be due to overproduction of NO through iNOS during the immune response as
part of the host defense (28, 30, 84). Previous literature demonstrates increased amounts of NO
lead to impaired cardiac function, including decreases in mean arterial pressure and blood
pressure (63). In one study, a hyperinsulinemic clamp revealed impaired glucose uptake/disposal
in wild type mice treated with sodium nitroprusside (SNP), an NO donor relative, suggesting that
alterations in the cardiovascular system effect the delivery of glucose to the skeletal muscle in
the presence of NO. Further, iNOS KO mice were rescued from impaired glucose uptake when
treated with LPS relative to wild type mice, suggesting that the overproduction of NO from
iNOS hinders delivery of glucose from blood circulation to the peripheral tissue by impairing
cardiovascular function, thus leading to insulin resistance (63).

Extracellular Nucleotide Signaling
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ATP was initially recognized as an extracellular signaling molecule when ATP was
identified as a neurotransmitter in the 1970s (20). In the decades following, the role of
nucleotides and nucleotide receptors has gone beyond neurotransmission. Nucleotide receptor
subtypes are expressed in most cell types. Nucleotide receptor activation has a wide variety of
effects and gained interest as therapeutic targets for inflammatory and cardiovascular disease.
Physiological Release and Function of Extracellular Nucleotides. ATP is
predominantly synthesized in the mitochondria and maintained at a micromolar intracellular
concentration (14). Intracellularly, ATP is used for energy to maintain cellular metabolism,
fueling anabolic reactions. Physiological release of nucleotides into the extracellular space
occurs in a controlled manner via secretory vesicles, ATP-transporters, hemichannels such as
pannexin and connexins, and channel proteins (Fig. 4) (85). Physiological extracellular
concentration of nucleotides is maintained at nanomolar concentrations. To maintain this
concentration and prevent over activation, the release and degradation of extracellular
nucleotides must remain in balance (80, 81). Extracellular triphosphates (ATP) can be converted
to diphosphates (ADP), into monophosphates (AMP), and to adenosine by ectoenzymes that are
expressed on the plasma membrane, such as NTPDase1, ecto-ATPDase, CD39, apyrase, and
CD37 (Fig. 4) (120). Extracellular nucleotides influence neurotransmission, hormone secretion,
and vascular homeostasis, immunity, and blood glucose level under physiological conditions (13,
17, 18, 21).
Pathophysiological Release and Function of Extracellular Nucleotides. During
pathophysiological events, extracellular ATP concentrations rise to micromolar concentrations
and become uncontrollable (Fig. 4) (22, 43, 68). The uncontrolled release occurs in cell injury,
cell death, necrosis, and apoptosis of the affected cells and tissue (85, 146). The regulated release
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of extracellular nucleotides occurs under pathological conditions, such as infection. Pathogens
such as bacteria or viruses contain pathogen-associated molecular patterns (PAMPs) (protein,
carbohydrates, DNA, or RNA) that are recognized by the innate immune system and elicit an
innate immune response. For example, LPS from bacteria, is a PAMP that elicits the controlled
release of ATP from immune cells via connexins and exocytosis (43).

Physiological
ATP

ADP

AMP

Adenosine

P2X

Pathophysiological

Fig. 4. Nucleotide signaling under physiological and pathophysiological conditions.
Extracellular nucleotides (ATP/UTP) and metabolites are signaling molecules and
ligands for nucleotide receptors (orange, green). Top: physiological conditions
nanomolar concentrations of ATP are tightly regulated n the extracellular space by
controlled release through channels (purple) and exocytosis, then conversion into
metabolites by ectonucleotidases (blue). Top: pathophysiological conditions lead an
increase to micromolar concentrations of extracellular nucleotides, increasing the
ligand for nucleotide receptors, thus increasing expression and activity. Under these
conditions, excess nucleotides from damaged, dying, or infected cells to act as danger
and find me signals for immune cells during infection and inflammation.
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Nucleotides released to extracellular space from damaged or dying cells serve as dangerassociated molecular patterns (DAMPs) to activate immune cells, referred to as a “danger
signal”. Extracellular nucleotides participate in the innate immune response to activate and
induce immune cell mobilization by acting as a “find-me” signal to draw them to damaged or
infected tissue (23, 68, 146) and inducing pro-inflammatory cytokine release (33) at the site of
infection to promote host defense. For example, extracellular nucleotides exert action on
nucleotide receptors to enable immune cells such as neutrophils and macrophages to migrate to
and subsequent phagocytosis of affected cells (85, 146). Additionally, extracellular nucleotide
are involved in the production of pro-inflammatory cytokines by exerting action on P2X7R and
P2Y2R on macrophages participates in the activation of NLRP3 inflammasome and leading to Il1β production, further activating the pro-inflammatory response (12, 36).
Purinergic Receptor Signaling: Nucleotide Receptors. The action of nucleotides and
their metabolites are mediated by purinergic receptors which are classified as two families: P1
and P2 receptors (Fig. 5). Purinergic receptors are broadly expressed in animal and mammalian
tissue on the plasma membrane (114). P1, adenosine receptors (A1, A2A, A2B, and A3), are G
protein-coupled receptors activated by adenosine (21, 70). P2 receptors are categorized into P2X
and P2Y subtypes. P2X receptors (P2X1-7) are ionotropic, ligand-gated ion channels activated
by ATP. Nucleotide P2Y receptors are classified as metabotropic G protein-coupled receptors
(GPCRs) and couple to G proteins Gi, Gq/11, and Gs. Mammalian cells express 8 subtypes of
the P2Y family (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14 receptors). P2Y
receptors are activated by a variety of nucleotides such as ATP, UTP, and their metabolites, ADP
and UDP. ADP activates P2Y1, P2Y12, P2Y13; ATP activates P2Y2, P2Y11; UDP activates P2Y6;
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UDP-glucose activates P2Y14; UTP activates P2Y2R and P2Y4R (44, 48, 71, 85). The receptor of
our interest, P2Y2R, is equipotently activated by UTP and ATP.

Purinergic
Receptors
Adenosine
Receptors

Nucleotide
Receptors

P1

P2

GPCRs

P2Y
A1, A2A, A2B,
A3

P2Y1

P2Y2R

P2Y11

P2Y12

P2Y4

P2Y13

Ligand
Gated Ion
Channels

P2X
P2Y6

P2X1 P2X2

P2Y14

P2X3

P2X4

P2X5

P2X6

Fig. 5. Purinergic receptor subtypes. Purinergic receptors are divided into adenosine
receptors, P1 (blue) and nucleotide receptors, P2 (orange). Nucleotide receptors are
further broken down further by receptor type. P2X receptors are ligand gated ion
channels activated by ATP. P2Y receptors are G protein-coupled receptors that upon
activation by various nucleotides (ATP, ADP, UTP, UDP, and UDP-glucose)
associate with intracellular G proteins. The receptor of interest for this research is the
P2Y2 receptor. This receptor is equipotently activated by ATP and UTP and expressed
throughout the body, exerting a wide variety of functions physiologically and
pathophysiological.

P2Y2 Receptor
The gene for P2Y2R is located on chromosome 11 in Homo sapiens and chromosome 7 in
Mus musculus (97, 105). Expression of P2Y2R is observed in most tissue types. For example:
bone, skeletal muscle, liver, pancreas, adipose tissue, tissue composing the urinary system,
cardiovascular system, and immune system, but not limited to these tissues (114). P2Y2R is a
GPCR, forming 7-transmembrane spanning helixes connected by intra- and extracellular loops,
extracellular N-terminus, and an intracellular C-terminus. The first extracellular loop contains an
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arginine-glycine-aspartate (RGD), allowing for the recognition of integrins. The C terminus
contains an Src homology domain (SH3) and associates with tyrosine kinases (48). P2Y2R
activation induces a conformational change that allows for the interaction with G proteins on the
intracellular side of the membrane. P2Y2R associates with G alpha subunits Gq/11, Gi/o, G12/13.
P2Y2R coupling with Gq/11 and Gi/o induces pathway PLCβ activation producing IP3 and DAG,
leading to intracellular calcium signaling, mobilization, and release. Integrins, av, bound to the
RGD domain in the first extracellular loop of the P2Y2 receptor is required for P2Y2R to couple
with Gi/o and G12/13, leading to activation of GTPases, Rho, and Rac, respectively (48). The
interaction of the RGD domain with integrin αVβ3/β5 promotes nucleotide-induced chemotaxis
which is recognized as a step in the inflammatory response, cell migration, and proliferation
(48).
The role of P2Y2R in the cardiovascular and immune systems has been well established.
Activated P2Y2R under pro-inflammatory states plays important role in tissue damage, chronic
inflammation, or the progression of diseases. For example, substantial research implies that
P2Y2R potentiates disease states, including inflammatory diseases, such as atherosclerosis, highfat diet-induced obesity, asthma, fatty liver disease, and sepsis (11, 49, 93, 98, 127). Studies
focused on P2Y2R in vascular inflammation and immune cells have been key in characterizing
the role of P2Y2R in the intra- and extravascular inflammatory response.
P2Y2R During the Intravascular Inflammatory Response. P2Y2R plays important
roles in the intravascular and extravascular events during the pro-inflammatory response.
Intravascularly, P2Y2R influences leukocyte motion via regulating adhesion and junctional
molecules. Endothelial cell P2Y2R activation leads to the expression of cell adhesion molecules
VCAM-1, ICAM-1, PE-CAM, and VE-cadherin. These molecules are important molecules for
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the regulation of vascular permeability and recruitment and extravasation of leukocytes (83, 126,
128, 147). P2Y2R plays a role in vascular permeability, a hallmark of inflammation. This is
evidenced by in vivo activation of P2Y2R by UTP in the cremaster muscle, leading to increased
venular permeability to albumin in wild type while there was no change in P2Y2R-/- mice (61). In
vitro studies demonstrate the cellular mechanism, activated P2Y2R is recruited to the endothelial
cell-cell junctions and co-localized with VE-Cadherin (83), a junctional cell adhesion molecule
important for regulating the integrity of the endothelial barrier.
To be recruited to a site of damaged or inflamed tissue, leukocytes must increase
interaction with endothelium lining the inner surface of vasculature and subsequently
extravasate. This process is referred to as the leukocyte adhesion cascade, a multi-step process
leading to transmigration and is key in the intravascular response to inflammation (82). Models
of the disease show that P2Y2R is important for the expression of VCAM-1, which is required
for leukocyte-endothelial interaction and extravasation. P2Y2R induces VCAM-1 expression
facilitating the adhesion of monocytes to the endothelial cells, eosinophils in lung inflammation,
and monocyte infiltration into the adipose tissue during high-fat diet-induced obesity (2, 93,
143). Studies using the P2Y2R global knock-out model have shown that the loss of P2Y2Rmediated VCAM-1 expression is protective during inflammatory diseases and reduced immune
cell infiltration, demonstrating that P2Y2R expression can exacerbate the pro-inflammatory
response (2, 93, 128, 143). Furthermore, recent data collected in our lab demonstrate P2Y2R’s
role in endothelial-leukocyte interaction in vivo in the cremaster muscle under stimulated
conditions (UTP) and basal conditions using the P2Y2R knock out model. Data from this study
demonstrates that P2Y2R modulates basal leukocyte rolling and adhesion under physiological
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conditions and is necessary for leukocyte rolling when challenged under stimulated conditions
with UTP.
P2Y2R in Extravascular Inflammation. P2Y2R facilitates extravascular proinflammatory response through the activation of pro-inflammatory and stress associated
signaling pathways, expression of pro-inflammatory cytokines and mediators, and activation and
augmentation of immune cells. ATP/UTP is released from damaged, inflamed, and infected
tissue and acts as danger signals. When cells are assaulted, ATP/UTP is released to the
extracellular space acting as a danger signal to recruit immune cells to the site of damage.
Extracellular ATP/UTP activates P2Y2R on the plasma membrane of neutrophils and augment
neutrophil chemotaxis (32, 69). The release of ATP from the leading edge of neutrophils bind to
P2Y2R in an autocrine fashion to amplify chemotactic signals (32). Further, apoptotic and
damaged cells release ATP, activating macrophages via P2Y2R, allowing phagocytosis of dying
cells (47).
Activation of P2Y2R leads to increase in the transcription of pro-inflammatory mediators
from immune cells and the peripheral tissue, potentiating the inflammatory responses. P2Y2R
accomplishes transcriptional activation by increasing NF-ĸB phosphorylation and translocation
to the nucleus, leading to the production of pro-inflammatory cytokines and mediators (39, 48).
Like TLR4 activation, P2Y2R activation leads to the production of cytokines such as Il-6, TNFalpha, Il-1β, and other pro-inflammatory mediators like nitric oxide via iNOS. As discussed
previously, these contributors to the development of insulin resistance (1, 49, 62). Mice with a
P2Y2R-deficiency on myeloid cells show a decrease in plasma Il-6 and TNF-α and decreased
expression of iNOS when challenged with LPS; showing that P2Y2R in cells derived from
myeloid cells promotes acute inflammation and the production of pro-inflammatory mediators.
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In vitro studies in macrophages show P2Y2R-mediated Il-1β production through activation of the
NLRP3 inflammasome (12, 36). Additionally, activation of the NLRP3 inflammasome is shown
to contribute to insulin resistance in obesity (142).Effects of P2Y2R on blood glucose regulation
are linked to the diverse role of P2Y2R in the pro-inflammatory response. Together, P2Y2R
involvement in pro-inflammatory responses may negatively impact glucose homeostasis during
these situations.
Current Knowledge of P2Y2R in Glucose Homeostasis
The role of P2Y2R as a regulator of glucose homeostasis has been emerging over the past
several years. Early studies suggested the role of extracellular nucleotides in insulin secretion
and glucose uptake in the periphery by exerting action on the P2 receptor, however, these studies
did not look specifically into P2Y2R’s role (24, 25). Recent studies show P2Y2R has a negative
impact on glucose homeostasis and insulin sensitivity (24, 25). These studies show P2Y2R
impacts insulin sensitivity in vitro in skeletal muscle cells and liver cells and in vivo during high
fat diet-induced obesity in mice. Here, we focus on the analysis of the current literature
describing P2Y2R’s role in glucose homeostasis and possible ways the receptor may be involved.
P2Y2R Potentiates Insulin Resistance by Altering the Insulin Signaling Pathway In
Vitro. An increase in extracellular nucleotide concentration and hyperglycemic conditions
activate P2Y2R and lead to insulin resistance in, as demonstrated by two recent studies in human
skeletal muscle cells and human HepG2 hepatocyte cells (73, 101). In both studies, P2Y2R
expression and function was confirmed by RT-PCR and measurement of intracellular calcium
mobilization after ATP stimulation. Incubating respective cells in high concentrations of glucose
lead to the release of extracellular ATP, as previously observed in earlier studies in HUVEC and
smooth muscle cells (SMC) (106, 112). P2Y2R activation under hyperglycemic conditions
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resulted in attenuated insulin induced AKT activation, the pathway required for glucose uptake,
suggesting that P2Y2R activation contributes to the development of insulin resistance. In both
cell types stimulating P2Y2R activation promoted the ERK1/2 signaling, a mitogenic pathway
involved in insulin resistance and inflammation. Together, these studies suggest ATP released
under hyperglycemic conditions activates P2Y2R, which leads to defective insulin-stimulated
glucose uptake by favoring activation of mitogenic and inflammatory pathways associated with
insulin resistance (11, 50).
P2Y2R Potentiates Obesity and Insulin Resistance in vivo. P2Y2R plays a role in the
pathogenesis of obesity and insulin resistance. Recent data demonstrated P2Y2R potentiates
HFD induced obesity (93, 153). Merz et al. tested insulin sensitivity in P2Y2R-/- and WT
(C57BL/6 background) mice following HFD (15 weeks). In brief, insulin sensitivity was
assessed by using an insulin tolerance test and quantifying plasma C-peptide levels, an indicator
of plasma insulin concentration (100). P2Y2R-/- mice had increased insulin sensitivity following
HFD, further illustrated by lower C-peptide. Zhang et al showed P2Y2R KO mice had lower
plasma insulin levels following HFD. They further demonstrated that key molecules responsible
for insulin stimulated glucose uptake such as the insulin receptor, IRS-1 (insulin receptor
substrate 1), and GLUT4 mRNA expression was increased in the KO mice relative to WT mice.
This suggest that P2Y2R under HFD conditions inhibits the expression of molecules responsible
for insulin stimulated glucose uptake and attenuates insulin receptor signaling. Collectively,
these studies implicate the putative role of P2Y2R in attenuating insulin signaling and
potentiating dysglycemia in HFD.
Adamson et. al assessed if P2Y2R on immune cells facilitate the development of HFD
induced-obesity and insulin resistance in chimeric myeloid-specific P2Y2R mice. In brief, WT or
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P2Y2R-/- bone marrow was transplanted into WT mice, creating chimeric knockout mice WTtransplant or KO-transplant. Following either regular diet or HFD (15-16 weeks), glucose
tolerance and plasma insulin were then assessed. Whole-body glucose tolerance and insulin
sensitivity were unchanged between KO-transplant mice and WT-transplant on an HFD group or
between mice on a regular diet. This indicates that the myeloid-P2Y2 receptor does not
contribute to impaired glucose tolerance and insulin resistance under HFD-induced obesity.
Contrarily, Merz et al assessed the function of P2Y2R-induced VCAM-1 expression of
the endothelium and its contributions to HFD-induced obesity and insulin resistance. Wild type
mice had increased immune cell infiltration into the adipose tissue relative to P2Y2R-/- mice.
Endothelial cells were isolated from the stromal vascular fraction and tagged to quantify VCAM1 expression using flow cytometry. This showed wild type mice on the HFD had increased
VCAM-1 expression relative to WT mice on a chow diet and P2Y2R-/- mice on an HFD. These
data suggested that P2Y2R activity is increased on an HFD, leading to increased VCAM-1
expression to facilitate immune cell infiltration. This pro-inflammatory environment mediated by
P2Y2R may contribute to the insulin resistance discovered in the wild type mice, but absent the
P2Y2R-/- mice. Collectively, these data suggest that endothelial P2Y2R (and subsequent VCAM-1
expression) and not Myeloid-P2Y2R facilitates immune cell infiltration, accumulation, and
inflammation in the adipose tissue leading to the development of insulin resistance.
P2Y2R-mediated Nitric Oxide Production and Glucose Homeostasis. P2Y2R is
involved in modulating blood flow through the production of nitric oxide. Additionally, nitric
oxide is important in regulating blood glucose homeostasis by participating in the delivery of
insulin and glucose to the peripheral tissue from the vasculature. P2Y2R is constitutively
expressed in the vascular endothelial cells and its agonists, ATP and UTP, maintain
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endothelium-dependent vasodilation under rest conditions (19, 22, 26). This is evidenced by the
fact that endothelial-specific P2Y2 knock-out mice exhibit hypertension due to attenuated
endothelial nitric oxide (147). This may provide a role for P2Y2R in the delivery of insulin from
the vasculature to the interstitial space through the expression of eNOS and NO production.
Delivery of insulin from the vasculature to interstitial space is an important step in
glucose uptake. The production of nitric oxide allows for increase perfusion, capillary
recruitment, vasodilation to peripheral tissue, and trans-endothelial insulin transport to facilitate
this step. In diseases such as obesity and insulin resistance, NO production is reduced (124).
Further, insulin resistance has been shown to develop in eNOS knockout mice (46). The
production of NO is partially mediated by insulin acting on endothelial insulin receptors to
activate eNOS in the vasculature through the PI3K-AKT pathway (144). Delivery of insulin
from the vasculature to interstitial space is an important step in glucose uptake. The production
of nitric oxide allows for increase perfusion, capillary recruitment, vasodilation to peripheral
tissue, and trans-endothelial insulin transport to facilitate this step and in diseases such as obesity
and insulin resistance, NO production is reduced (124).
It is unclear if P2Y2R-mediated eNOS signaling participates in the delivery of insulin to
the peripheral tissue. Given that P2Y2R is an important regulator of endothelium-dependent
vasodilation, this suggests a potential role of P2Y2R in facilitating changes in the vasculature that
positively influence insulin delivery and subsequent glucose uptake in the peripheral tissue. This
is supported by a study performed in diabetic and healthy humans, where the objective was to
assess the vasodilatory effect of P2Y2R agonist ATP and UTP in the vasculature of the skeletal
in diabetic patients (137). In this study, patients were infused with ATP and UTP through the
femoral artery, both previously being defined as vasodilators. Diabetic patients’ vasodilatory
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response to ATP and UTP are decreased along with leg blood flow relative to healthy patients,
suggesting attenuated nucleotide signaling in diabetic patients. The attenuated nucleotide
signaling, potentially, through P2Y2R may lead to decreases in NO bioavailability and contribute
to insulin resistance seen in patients with T2D. This may suggest endothelial P2Y2R is important
to maintain euglycemia via the delivery of insulin to the peripheral tissue and requires further
investigation.
Contrarily, under acute inflammatory conditions, P2Y2R-mediates iNOS expression may
suggest a negative impact for P2Y2R on maintaining euglycemia. The production of NO through
iNOS during the immune response is part of the host defense. P2Y2R-mediated iNOS expression
is evidenced by in vitro studies in macrophages. LPS challenge in vitro macrophages increases
P2Y2R mRNA expression. Further, iNOS protein expression is increased when challenged with
LPS plus ATP or UTP with a correlating increase in NO production (49). Supporting this,
P2Y2R-deficiency on myeloid cells in mice leads to a decrease in NOS2 (iNOS) gene expression
when challenged with an acute dose of LPS compared to control mice suggesting partial
protection from acute inflammation (1).
The pro-inflammatory environment and cardiovascular impairments created by iNOS
lead to impaired glucose uptake and insulin (30). NO production by iNOS occurs in excess and
has negatively affected cardiovascular function (decrease in cardiac output, blood flow, and
perfusion) leading to impaired insulin-stimulated glucose uptake in the muscle due to impaired
glucose delivery. This is evidenced in two studies where endotoxemia in mice decreased glucose
uptake in skeletal muscle due to a decrease in glucose delivery to the tissue due to impaired
cardiac function (63, 99). In this way, it is hypothesized that P2Y2R-mediated iNOS expression
and overproduction of NO lead to impaired muscle glucose uptake. Inhibiting P2Y2R activation
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under these conditions may attenuate the cardiac impairments that facilitate impaired glucose
uptake. The pro-inflammatory environment and cardiovascular impairments created by iNOS
lead to impaired glucose uptake and insulin (30). NO production by iNOS occurs in excess and
has negatively affected cardiovascular function (decrease in cardiac output, blood flow, and
perfusion) leading to impaired insulin-stimulated glucose uptake in the muscle due to impaired
glucose delivery. This is evidenced in two studies where endotoxemia in mice decreased glucose
uptake in skeletal muscle due to a decrease in glucose delivery to the tissue due to impaired
cardiac function (63, 99). In this way, it is hypothesized that P2Y2R-mediated iNOS expression
and overproduction NO, leading to impaired muscle glucose uptake. Inhibiting P2Y2R activation
under these conditions may attenuate the cardiac impairments that facilitate impaired glucose
uptake.
The previous studies discussed provide evidence that under pathophysiological
conditions, P2Y2R activation is increased and negatively impacts glucose homeostasis by
potentiating insulin resistance. The presence of high glucose concentrations leads to ATP and
UTP release that increase the expression and activation of P2Y2R. However, there is a lack of
information on how P2Y2R modulates glucose homeostasis under physiological conditions. It is
unknown if P2Y2R activity contributes to glucose homeostasis in the postabsorptive and
absorptive state, or if these conditions contribute to increased or decreased receptor activity. In
the current study we set out to define the role of P2Y2R in glucose homeostasis under
physiological conditions. We utilized the global P2Y2R knock out mouse model to evaluate if the
absence of the receptor altered fasting glucose values and the response to glucose tolerance test
relative to wild type mice, allowing us to elucidate the role of P2Y2R in glucose homeostasis. In
this study, we found that P2Y2R may contribute to physiological glucose homeostasis in the
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absorptive state specifically in male mice; further we found that sex-specific differences in
fasting, or the post-absorptive state may be mediated by P2Y2R.

Sex-Specific Regulation of Glucose Homeostasis
In biomedical research, male biased studies were the norm to circumvent any perceived
interference from the female reproductive system or the assumption that what was discovered in
males applied to females. However, in recent years, it has been realized that both female and
male research subjects are necessary to conduct research that accounts for the sexual
dimorphisms we see in health and disease and are important in considering symptoms of certain
disease and efficacy of certain drugs. The combination of genetic and hormonal sex differences
alters a variety of physiological parameters between the sexes.
Reproductive (sex) hormones such as estrogen partially contribute to sexual dimorphisms
between men and women. There are several key sexual dimorphisms in glucose homeostasis that
are evidenced to be influenced by sex hormones. Sex differences are observed in fasting blood
glucose, glucose tolerance, and insulin sensitivity, and in the development of metabolic diseases
such as T2D (34, 60). For example, it is reported that increased insulin sensitivity in women
relative to men is correlated to the differing concentrations of estrogen between the sexes (88,
129). This is exemplified in age-related studies by observing the changes of estrogen
concentrations through the life span in women and the effect on insulin sensitivity. For instance,
women early in their reproductive years are more insulin sensitive relative to woman who have
gone through menopause, where there is a significant decrease in estrogen. When comparing
young adult women and age-matched men, women are less prone to the development of insulin
resistance. In-post-menopausal women the incidences of insulin resistance began to match men,
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suggesting that estrogen has a protective role against insulin resistance (89). This highlights the
importance of reproductive hormones in the regulation of the glucose homeostasis and how they
contribute to sexual dimorphisms.
Further, female humans and mice have lower fasting blood glucose levels relative to
males and females, in addition to being more insulin sensitive. However, blood glucose levels
remain higher relative to men 2 hours post-oral glucose tolerance test OGTT in women (89).
This suggest that women have decreased glucose tolerance relative to men, despite documented
increased insulin sensitivity. However, when an OGTT is performed in humans, the bolus of
glucose ingested contains a standardized concentration of glucose for all patients. This may
indicate that the rate of glucose uptake in women is decreased in women due to body fat-content
and height differences. Whereas in mice the bolus of glucose ingested or administered by
injection is based on body weight, which may lead to a more accurate reflection of glucose
tolerance. During intraperitoneal GTT (IPGTT) in C57BL/6 mice, females have better glucose
tolerance and insulin sensitivity compared with males (86). When an OGTT is performed in
humans, the bolus of glucose ingested contains a standardized concentration of glucose for all
patients whereas in mice the bolus of glucose ingested or administered by injection is based on
body weight, which may lead to a more accurate reflection of glucose tolerance.
Sex differences contribute to body fat and skeletal muscle distribution and abundance,
which further contribute to sex-specific differences in glucose homeostasis. For instance, white
adipose tissue distribution may influence differences in metabolic parameters among women. For
example, fat is distributed in the subcutaneous space primarily in women, however, accumulates
in the visceral organs in men. The accumulation of visceral fat is tightly correlated with insulin
resistance and T2D. Accordingly, men are more likely to develop T2D and cardiovascular
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disease. Similarly, it has been reported skeletal muscle differs between men and women in
energy metabolism, fiber composition, and contractile speed (56). Supporting this, to a study
from 1990 showed that men and women exhibit differences in glucose uptake. In this study,
human subjects were given a glucose challenge and after 3 hours, women had higher glucose
uptake relative to men (113).
Genetic sexual dimorphisms in glucose homeostasis are attributed to the X and Y
chromosomes, gene expression, and epigenetics. Sex-specific differences gene expression in key
molecules in various tissues involved in glucose homeostasis. For instance, it has been shown
expression of GLUT4 mRNA in female mice is higher than that in males. When these mice were
challenged with exogenous insulin, females have significantly higher phosphorylated AKT
relative to males (86). The increase in gene expression in females may be attributed to estrogen’s
ability to regulate transcription. Estrogen binds to nuclear estrogen receptors and become
transcription factors, leading to the recruitment of transcriptional coactivators to promoter and
enhancer regions to activate gene expression (67). Given that women have higher levels of
estrogen, this may enhance transcription of relevant receptors, transporters, and signaling
molecules involved in glucose homeostasis in women, leading to better insulin sensitivity.
Regulation of genes not directly involved in metabolic pathways may have sex-specific
influence on glucose homeostasis. For instance, in Casp2-/- mice females are protected from
impaired glucose tolerance in older adults. In contrast, knocking out this gene promotes impaired
glucose tolerance in older males (152). Further, a study evaluating G-protein coupled receptor
kinase 2 (GRK2) in sex- and age- related differences in glucose homeostasis under high fat diet
feeding show young female mice have better insulin sensitivity correlating with lower GRK2
expression compared to age-matched male and middle-aged female animals This demonstrates
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expressional differences in genes and proteins may be influenced by sex hormones and
contribute to sex-specific differences in development of impaired glucose tolerance (8, 152).
Collectively, sex-specific differences in glucose homeostasis are complex and are
regulated by a variety of biological factors. In the studies discussed here, we see evidence that
sex differences in glucose homeostasis are mitigated by sex hormones and sexual dimorphisms
in gene expression. How these sex biological factors influence P2Y2 receptor signaling in the
regulation of glucose homeostasis remains unknown and requires investigation. In the current
study we set out to illuminate the novel physiological function of P2Y2R in glucose homeostasis
in both male and female mice and to evaluate potential sexual dimorphism in P2Y2R activation
in glucose homeostasis. In the current study we observed different response to glucose tolerance
test in male P2Y2R-/- mice relative to wild type littermates, but not in female wild type and
knock-out littermates. We observed sex specific differences in fasting blood glucose and glucose
tolerance test in wild type males and females and P2Y2R-/-. The discovery of sex differences in
fasting blood glucose in wild type mice, but not in P2Y2R-/- may suggest involved of P2Y2R.
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METHODS

Animals
The Institutional Animal Care & Use Committee (IACUC) of Missouri State University
approved all procedures of the study designated as protocol 18-006.0 (Appendix). Animals were
purchased from Jackson Laboratory (Stock #: 009132 Bar Harbor, Maine). The P2Y2R+/(C57BL/6J background) mice were originally established by the lab of Dr. Beverley Koller
(149). All mice were fed a standard chow diet (Laboratory Rodent Diet 5001, Purina, cat #
0001319 St. Louis, Missouri). Mice were housed in the Professional Building vivarium in
filtered cages. The mice were on a twelve-hour light-dark cycle (6 am-6 pm dark, 6 pm-6 am
light) at 72 °F.
Both female and male P2Y2R-/- and C57BL/6 (wild type) littermates were utilized during
this study (Fig. 6). Each experiment was performed on a pair of same-sex P2Y2R-/- and wild type
littermates. Mice were between the ages of 8 and 12 weeks old for all experiments performed.
Female mice weighed between 17.8 and 25.3 grams; male mice weighed between 22.5 and 28.9
grams. A total of 38 mice were used for the study while the data generated from 36 mice were
included in the thesis. Nine wild type and nine P2Y2R-/- male mice were used in the experiments
for this thesis. Ten wild type and 10 P2Y2R-/- female mice were used in the experiments for this
thesis. One wild type and one P2Y2R-/- female mice were not included in data analysis. These
mice had missing ear tags at the time of the experiment. After completing the experiment, the
two mice were mixed and placed into the wrong cage and could not be re-genotyped to confirm
the genotype associated with the experiment; the data from these two experiments were not
included in the data analysis (Fig. 6).

33

Wild Type

P2Y2R-/-

N=9

N=9

P2Y2R-/-

Wild Type

N=9

N=9

MALE

FEMALE

Fasting Blood Glucose and Glucose
Tolerance Test

Fig. 6. Experimental groups of mice. Female and male P2Y2R-/- mice and wild type
littermate control mice were utilized during this study. Experiments were performed on a
pair of same sex littermates.

Mouse Colony Breeding and Genotyping
Female and male heterozygous P2Y2+/- were bred at Missouri State University, producing
50% heterozygous, 25% wild type (WT), and 25% P2Y2R-/- mice. Mice were weaned at 28 days
old. One week before weaning ears were tagged for identification, 0.5-2mm of their tails were
snipped using sterile razors and placed into 1.5 ml tubes for genotyping. Male and female WT
and P2Y2R-/- offspring were utilized for this study. Heterozygous offspring were utilized as
breeders to produce P2Y2R-/- and wild type mice.
Three primers were used to amplify DNA for genotyping. One antisense primer and 2
sense primers, due to mutant P2ry2 allele (Table 2) in the knockout mice. These primers were
purchased through IDT DNA. The P2Y2R knock out model was created by inserting a neomycin
cassette into the P2ry2 cDNA at base pairs 552 to 1149, thus disrupting gene function (149). For
our genotyping, one sense primer was created to amplify part of the neomycin gene, while the
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other sense primer bound to the intact WT P2y2 gene. The same antisense primer paired with the
sense primers generated two distinct bands to for wild type and knock out alleles: 418 bp for
wild type and 598 bp for knockout. Fig. 7 shows the gel electrophoresis results for wild type,
knockout, and heterozygous mice with the primers designed for genotyping.
Genotyping was accomplished in 3 steps: DNA extraction, PCR, and gel electrophoresis.
DNA was extracted from mouse tail snips using components of Thermo Scientific Phire Animal

Table 2. Primers used for genotyping the P2Y2R mouse colony.
Primers

DNA Sequence

oRU23

anti-sense

5’ -AGCCACCCGGCGGGCATAAC- 3’

oRU24

sense

5’ -GAGGGGGACGAACTGGGATAC- 3’

oRU25

sense

5’ -AAATGCCTGCTCTTTACTGAAGG- 3’

L

HET

KO

WT

500 bp

Fig. 7. Genotyping results for the P2Y2R breeding colony. Wild type and the knockout
P2Y2R gene were amplified, and the products electrophoresed on a 1% agarose gel in 1
X sodium borate (SB) buffer. Left, 100 base pair (bp) ladder (L). Products from single
heterozygous (HET), P2Y2R-/- (KO), and wild type (WT) mice are indicated above the
lane. Expected band sizes are: 598 bp KO, 414 bp WT; HET mice will contain both
bands.

35

Tissue Direct PCR Kit: Dilution Buffer (Thermo Scientific Cat # F-132-5ML, Waltham,
Massachusetts) and DNA Release Additive (Thermo Scientific, Cat # FERB93, Waltham,
Massachusetts). Twenty microliters of dilution buffer and 1 µl of DNA release were added
directly to the tail snips. The centrifuge tubes were spun down and then vortexed to make sure
tail snips were in solution. The tail snips incubated at room temperature for 5 minutes, then at
98 ℃ for 2 minutes. The centrifuge tubes were vortexed again with the liquid containing the
DNA extract and tail snip left in the tube. Following this, DNA extract was used for PCR or
frozen at -20 ℃.
Extracted DNA was amplified by PCR using DreamTaq master mix (Thermo Scientific,
Cat # K1071, Waltham, Massachusetts), and primers oRU23, oRU24, oRU25. For the PCR, a
master mix was created based upon the number of tail snips and controls. In Table 3 an example
of how the master mix was set up is provided. Each PCR reaction contained 12.5 µl of Dream
Taq Master Mix, 0.25 µl of oRU23 (100 µM), oRU24 (100 µM), oRU25 (100 µM), 10.0 ul of
H2O. After the master mix was aliquoted to the PCR tubes, 1.75 µl of DNA was added to each
Table 3. Example for creating a 25 µl Master mix for 7 samples, controls, and1 µl
extra
25 µl PCR reaction

per reaction

master mix (7X)

Dream Taq Master Mix

12.5 µl

87.5 µl

oRU23 (100 µM)

0.25 µl

1.75 µl

oRU24 (100 µM)

0.25 µl

1.75 µl

oRU25 (100 µM)

0.25 µl

1.75 µl

H2O

10.00 µl

70 µl

Total:

23.25 µl

---

template DNA

1.75 µl added to each tube after the master
mix
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tube for each mouse. The thermocycler was set according to the parameters depicted in Table 4.
Following PCR, gel electrophoresis was performed. PCR reactions were removed from
the thermocycler and vortexed. For Dream Taq containing loading dye, reactions were loaded
into the gel as is. For PCR reactions where Dream Taq did not include loading dye, 5 µl of 6X
loading dye was added to each reaction. The PCR product was run on 1% to 1.5% agarose gel
containing Ethidium Bromide (EtBr) at the following volumes, depending on the size of the gel:
2 ul of EtBr was added to 50 ml gel, 10 ul of EtBr was added to 100 ml and 125 ml gels. Each
agarose gel was run at 230V for 30 to 35 minutes in 1X sodium borate (SB) buffer. Fig. 7
demonstrates the gel electrophoresis results for wild type, knockout, and heterozygous mice.

Table 4. Thermocycler settings for mouse colony genotyping
initial
denaturation annealing extension
repeat
denaturation
Temp
95 ℃
95 ℃
60 ℃
72 ℃
Repeat
2-4 36X
Time
2 min
30 sec
30 sec
30 sec

final
extension
72 ℃
5 min

hold
4℃
∞

Intraperitoneal Glucose Tolerance Testing
To evaluate the glucose response, an intraperitoneal glucose tolerance test (IPGTT) was
performed (Fig. 8) (7, 10, 11, 16, 145). Mice were placed into separate cages for fasting for 5
hours before IPGTT. These cages were clean, free of food, but access to water ad libitum. A
stock volume of 50% dextrose (Patterson Veterinary Supply, #78008986, Kansas City, Missouri)
was diluted to 20% (w/v) dextrose in saline for intraperitoneal (IP) injection at 2g/kg body
weight. Ten to fifteen minutes before the GTT mice were removed from their cage and place in a
raised, uncovered container for easy access, then lidocaine was applied to the tail for local
anesthesia. Lidocaine was applied by gently taking the mouse by the tail and wiping it onto the
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tail. After 10 to 15 minutes, the lidocaine was wiped off and 70% EtOH was used to sanitize the
tail. One to two millimeters of the tail tips were snipped with surgical scissors. The tail was
gently massaged to promote blood flow to the tip to measure blood glucose levels using blood
glucose test strips coupled with a glucometer (ReliOn, Walmart, Bentonville Arkansas). The
fasting (t = 0) blood glucose reading was assessed immediately before the IP injection of
dextrose. Fig. 8 shows a schematic timeline of each important time point in the experiment.

t = -5 hr

Fast begins

t = -15 min

Blood glucose readings at 10, 20, 30, 45, 60, 75,
and 90 minutes

t=0

Lidocaine to tail

(1) Fasting glucose reading
(2) Dextrose injection

Fig. 8. Schematic timeline of intraperitoneal glucose tolerance test. Mice were removed
from vivarium and placed into the cages with water but no food to initiate the 5 hours
fast (t = -5 hr). Ten to fifteen minutes (t = -15 min) prior to the glucose tolerance test
lidocaine was applied to the tail. Fasting blood glucose was read at the end of the 5 hours
fast (t = 0) and immediately after IP injection of 20% dextrose was administered.
Following blood glucose levels were read at the indicated time points over 90 minutes.
After the fasting blood glucose reading the IP injections were performed. For the IP
injections mice were physically restrained by experimenter. The mice were placed on the bench
top with the dominant hand gently holding the mouse just below the base of the tail. With the
non-dominant hand, the mice were picked up by the scruff of the neck with the thumb and index
finger. The tail was then placed between the palm and the pinky finger. From this point the
abdomen was exposed for the IP injection. The IP injection was administered in the lower right
or left quadrant of the abdomen at a 45℃ angle. After the IP injection blood glucose reading
were taken at 10, 20, 30, 45, 60, 75, and 90 minutes after IP injection. After the final glucose
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reading, the tail was anesthetized again using lidocaine. Ten minutes after the second application
of lidocaine, the tail blood samples were collected in SARSTEDT Microvette CB 300 K2E
centrifuge tubes (Thermo Scientific, Cat# NC9141704, State) for an assessment of insulin level.
To obtain plasma, 100 to 150 µl of blood was centrifuged at 10 g for 10 minutes at 4 °C
(Eppendorf Centrifuge 5415 R, Cat#E216059, Germany). The plasma was aliquoted into a 1.5
ml Eppendorf tube and stored at -80 °C for future quantification of insulin levels. After each
experiment, mice were anesthetized using isoflurane followed by euthanasia by cervical
dislocation.

Statistical Analyses
All values are presented as Mean ± SEM. Prism GraphPad and College of Health and
Human Services R-STATs department were used to evaluate significant differences
between groups: female WT vs KO, male WT vs KO, WT male vs female, and KO male vs
female. Glucose tolerance test data were analyzed using two-way ANOVA with repeated
measures. This is to evaluate the effect of the genotype on blood glucose response, which
consists of two (two independent variables, wild type, and P2Y2R-/- mouse strains) by eight
repeated measures at indicated time points. The analysis for the effect of sex on glucose response
also used two-way ANOVA with repeated measures. Sisak’s multiple comparison test was
utilized to determine if a significant difference in glucose concentration at each time point
between genotypes or sexes. Fasting blood glucose levels between the four groups to evaluate
the effect of genotype and sex were analyzed with a 2-way ANOVA, and then two-tailed
unpaired t-test to evaluate effect of genotype on fasting blood glucose and the effect of sex on
fasting blood glucose. Statistical significance was reported as p-value less than 0.05 (p < 0.05).

39

The results Tables generated in Prism using a 2-way ANOVA with repeated measures for IPGTT
data and a 2-way ANOVA for fasting are in the results (Tables 5,8,9, 10, 11). Results tables
generated from 2-tailed t-test for sex differences in fasting are in the results (Tables 6,7)
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RESULTS

Influence of P2Y2 Receptor and Sex under Fasting Conditions
Clinically, fasting blood glucose (FBG) is utilized to screen for pre-diabetes and diabetes.
In animal research, fasting blood glucose levels may allow investigators to evaluate blood
glucose homeostasis under various conditions. We used fasting blood glucose values to assess
P2Y2R and sex in glucose homeostasis in the post-absorptive state.
P2Y2 Receptor Activity Under Fasting Conditions. To assess fasting blood glucose in
P2Y2R-/- and wild type mice, blood glucose levels at t = 0, fasting without food for 5 hours in the
same-sex littermates were measured (Fig. 9, Table 5). Fasting blood glucose is not expected to
differ between wild type and knock out mice under physiological conditions. No significant
difference in fasting blood glucose levels due to genotype in male wild type (106.6 ± 4.6 mg/dl;
n = 9) and P2Y2R-/- (100.4 ± 4.7 mg/dl; n = 9) and, in female wild type (88.9 ± 5.7 mg/dl; n = 9)
and P2Y2R-/- (95.1 ± 4.5 mg/dl; n = 9) mice. These data (Fig. 9, Table 5) suggest P2Y2R does not
affect fasting blood glucose in sex- and littermate-matched mice.
Sex Differences Under Fasting Conditions. Sex differences in FBG were assessed
between all four groups. It is expected that sex specific differences in fasting blood glucose are
present in both wild type and P2Y2R-/- mice. Sex differences were significant when all four
groups were analyzed with a 2-way ANOVA (Fig. 9, Table 5). To assess the effect of sex on
FBG within wild type mice and P2Y2R-/- mice using a 2-tailed t test between wild type male and
female (Table 6) and P2Y2R-/- males and females (Table 7). In wild type mice, the fasting
glucose levels were significantly lower in females relative to males (Fig. 9, Table 6). However,
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P2Y2R-/- females and males did not differ significantly in fasting glucose levels (Fig. 9, Table 7).
The results suggest P2Y2R may contribute to sex differences affecting FBG

Sex Differences in Fasting Blood Glucose
✱
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Fig. 9. Sex differences in fasting blood glucose levels. P2Y2R did not alter fasting blood
glucose in males. Fasting blood glucose levels (at t = 0) were measured following 5 hours
of fasting using a glucometer. FBG value were analyzed between the 4 groups using a 2way ANOVA, showing sex, not genotype has a significant effect on FBG (p < 0.05). FBG
was then analyzed for sex differences using 2-tailed t-test to evaluate the effect of sex in
wild type and knock out mice. Data are presented as mean ± SEM (n = 9) and * denotes
statistical significance (p < 0.05).

Table 5. 2-way ANOVA for fasting blood glucose between all 4 groups results.
Source of
% Of total
P value
P value
Significant?
Variation
variation
summary
Interaction
3.987
0.2212
ns
No
Sex
14.06
0.0255
*
Yes
Genotype
8.162e-005 0.9955
ns
No
ANOVA table
SS
DF
MS
F (DFn, DFd)
P value
Interaction
339.2
1
339.2
F (1, 32) = 1.557
P=0.2212
Sex
1196
1
1196
F (1, 32) = 5.489
P=0.0255
Genotype
0.006944
1
0.006944 F (1, 32) = 3.187e-005 P=0.9955
Residual
6973
32
217.9
* Source of variation (top, bold) and the ANOVA table (bottom, bold).
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Table 6. 2-tailed unpaired t-test for WT sex differences in fasting glucose
Unpaired t test
P value
0.0284
P value summary
*
Significantly different (P < 0.05)?
Yes
One- or two-tailed P value?
Two-tailed
t, df
t=2.409, df=16

Table 7. 2-tailed unpaired t-test for P2Y2R-/- sex differences in fasting glucose
Unpaired t test
P value
0.4235
P value summary
ns
Significantly different (P < 0.05)?
No
One- or two-tailed P value?
Two-tailed
t, df
t=0.8213, df=16

Influence of P2Y2 Receptor and Sex on Glucose Tolerance
To assess the effects of P2Y2R and sex on glucose homeostasis in the absorptive state
(fed conditions), IPGTT was performed by measuring blood glucose concentration over a 90minute time-course after intraperitoneal injection (IP) of glucose (Fig. 10).
P2Y2 Receptor Activity in Glucose Tolerance, Fed Conditions. To determine if P2Y2R
regulates glucoses in the absoprtive state, the time course response to IPGTT in P2Y2R-/- mice
was compared with sex- and littermate-matched wild type mice (Fig. 10, Table 8, Table 9). The
results for the glucose tolerance test are expected to remain the same between male wild type
and P2Y2R-/- mice. Male P2Y2R-/- mice displayed higher blood glucose levels over 90 min in
response to glucose challenge relative to wild type males, shown in Fig. 10A and Table 8 (p <
0.05). These data suggest P2Y2R is involved in maintaining physiological glucose tolerance.
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Unlike male mice, females did not have significant interaction between time and
genotype when data were analyzed with two-way ANOVA with repeated measures.Although,
the time course response to IPGTT in female wild type mice showed a trend of lower blood
glucose levels compared with female P2Y2R-/- mice, there was no significant difference, as
shown in Fig. 10B and Table 9 (p > 0.05). These data may suggest P2Y2R is not involved in
matianing phsyilogical glucose tolerance in females, but plays a male-specific role in glucose
tolerance. Fig. 10C shows all four groups plotted onto one graph.
Sex-Specific Differences in Glucose Tolerance in Wild Type Controls and P2Y2R-/Mice. The effect of sex on glucose homeostasis in the absorptive state was analyzed by
comparing glucose tolerance test between sexes in wild type and P2Y2R-/- mice (Fig. 11, Table
10, 11). Sex differences between male and female mice during a glucose tolerance are expected.
Female mice are expected to have lower blood glucose levels over time relative to males. The
time course response to IPGTT in female wild type mice was lower than male wild type mice (p
< 0.05) (Fig. 11A Table 10 ). The female P2Y2R-/- mice displayed lower blood glucose levels
over the time relative to males P2Y2R-/- mice (p < 0.05), shown in Fig. 11B and Table 11.
Consistent with previous literature and data reported, blood glucose levels over time are lower in
female wild type mice, indicating improved insulin sensitivity and glucose clearance relative to
wild type males. In P2Y2R-/- mice, we see these sex differences as well. However, these data
suggest the sex differences in P2Y2R-/- mice may be exacerbated due to the statistically
significant increase in blood glucose levels in P2Y2R-/- males relative to wild type and requires
further investigation.
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P2Y2R is Involved in Glucose Response During IPGTT in Males, but
not Females
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Fig. 10. P2Y2R is involved in glucose response during IPGTT in males, but not females.
Intraperitoneal glucose tolerance test (IPGTT) was used to determine the role of P2Y2R
in glucose homeostasis. Mice fasted for 5 hours before Ip administration of 20% (v/v)
dextrose at 2 g/kg body weight. A: Blood glucose responses to IPGTT over 90 minutes
in male wild type and P2Y2R-/-. B: Blood glucose responses to IPGTT over 90 minutes in
female wild type and P2Y2R-/- mice. C: All four group’s blood glucose response plotted
onto one graph. Data are presented as mean ± SEM and * denotes statistical significance
(p < 0.05).
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Table 8. WT and P2Y2R-/- male mice 2-way ANOVA repeated measures results.
% Of
GeisserSource of
P value
total
P value
Significant?
Greenhouse's
Variation
summary
variation
epsilon
Time x Genotype 1.776
0.0151
*
Yes
Time
74.50 <0.0001
****
Yes
0.3766
Genotype
1.430
0.1770
ns
No
Subject
11.47 <0.0001
****
Yes
ANOVA table
SS
DF
MS
F (DFn, DFd)
P value
Time x Genotype 20402
7
2915
F (7, 112) = 2.625
P=0.0151
Time
855907
7
122272
F (2.636, 42.17) = 110.1 P<0.0001
Genotype
16427
1
16427
F (1, 16) = 1.995
P=0.1770
Subject
131755
16
8235
F (16, 112) = 7.417
P<0.0001
Residual
124352
112
1110
* Source of variation (top) and the ANOVA table (bottom)

Table 9. WT and P2Y2R-/- female mice 2-way ANOVA repeated measures results.
% Of
GeisserP value
Source of Variation total P value
Significant?
Greenhouse's
summary
variation
epsilon
Time x Genotype 1.230 0.4294
ns
No
Time
65.41 <0.0001
****
Yes
0.3237
Genotype
0.4615 0.4683
ns
No
Subject
13.38 <0.0001
****
Yes
ANOVA table

SS

DF

MS

F (DFn, DFd)

P value

Time x Genotype

11144

7

1592

P=0.4294

Time

592631

7

84662

F (7, 112) = 1.008
F (2.266, 36.25) =
53.61
F (1, 16) = 0.5519
F (16, 112) = 4.799

Genotype
4182
1
4182
Subject
121242
16
7578
Residual
176866
112
1579
*Source of variation (top) and the ANOVA table (bottom)
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P<0.0001
P=0.4683
P<0.0001

Sex Influence Glucose Response During IPGTT in Both Wild Type
and P2Y2R-/- Mice
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Fig. 11. Sex influences glucose response during IPGTT in both wild type and P2Y2R-/mice. The effect of sex on glucose homeostasis was assessed using age-matched male (n
= 9) and female (n = 9) wild type (A) and P2Y2R-/- mice (B). Mice have fasted for 5
hours before ip administration of 20% (v/v) dextrose at 2 g/kg body weight. Blood
glucose was measured at the indicated time points. Data are presented as mean ± SEM
and the symbol * denotes statistical significance (p < 0.05)
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Table 10. Sex differences in wild type mice 2-way ANOVA repeated measures results.
GeisserSource of % Of total
P value
P value
Significant?
Greenhouse's
Variation
variation
summary
epsilon
Time x Sex
1.343
0.2882
ns
No
Time
65.26
<0.0001
****
Yes
0.3136
Sex
4.110
0.0321
*
Yes
Subject
11.93
<0.0001
****
Yes
ANOVA
SS
DF
MS
F (DFn, DFd)
P value
table
F (7, 112) =
Time x Sex
12861
7
1837
P=0.2882
1.238
F (2.195, 35.12)
Time
624938
7
89277
P<0.0001
= 60.15
Sex
39353
1
39353
F (1, 16) = 5.513
P=0.0321
F (16, 112) =
Subject
114212
16
7138
P<0.0001
4.810
Residual
166229
112
1484
* Source of variation (top) and the ANOVA table (bottom)

Table 11. Sex differences in P2Y2R-/- mice 2-way ANOVA repeated measures
results.
Source of
Variation

% Of total
variation

P value

P value
summary

Significant?

Time x Sex
1.343
0.2882
ns
No
Time
65.26
<0.0001
****
Yes
Sex
4.110
0.0321
*
Yes
Subject
11.93
<0.0001
****
Yes
ANOVA
SS
DF
MS
F (DFn, DFd)
table
Time x Sex
12861
7
1837
F (7, 112) = 1.238
Time
624938
7
89277
F (2.195, 35.12) = 60.15
Sex
39353
1
39353
F (1, 16) = 5.513
Subject
114212
16
7138
F (16, 112) = 4.810
Residual
166229
112
1484
*Source of variation (top) and the ANOVA table (bottom)
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GeisserGreenhouse's
epsilon
0.3136

P value
P=0.2882
P<0.0001
P=0.0321
P<0.0001

DISCUSSION AND CONCLUSION

Currently, there are no published data demonstrating P2Y2 receptor activation in the
physiological regulation of glucose homeostasis. In this current study we set out to define the
novel role of the P2Y2 receptor in physiological glucose regulation in both male and female
mice. Previous studies demonstrate that P2Y2R signaling is increased under pathophysiological
conditions, such as obesity and insulin resistance demonstrating P2Y2R is a key player.
However, it is unknown if P2Y2R signaling is involved in glucose homeostasis under
physiological conditions. Further, it is known that sex differences in gene expression and
reproductive hormones contribute to the physiological regulation of glucose homeostasis. In the
previous studies discussed, experiments were conducted in solely male or female mice and did
not account for sex-specific differences in glucose homeostasis.
In the current study we set out to define the novel role of sex differences in P2Y2R
signaling. The objective of this study is to answer the questions (1) what physiological role does
P2Y2R have in vivo in fasting blood glucose and glucose tolerance and (2) do sex-differences in
P2Y2R signaling change these parameters between female and male mice? Using four groups of
mice, 2 sexes, 2 mouse strains (WT and P2Y2R-/- mice), we found the absence of P2Y2R
impaired glucose tolerance, thus glucose homeostasis in the absorptive state, in males, but not in
female mice. Further, sex-difference in fasting blood glucose in wild type mice, but not in and
P2Y2R-/- mice. Moreover, sex difference in GTT in both wild type and P2Y2R-/- mice were found,
however, P2Y2R-mediated modulation during GTT was only observed in males, but not females.

Assessment of Fasting Blood Glucose
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Fasting blood glucose is used to evaluate blood glucose regulation under postabsorptive
condition. Fasting blood glucose levels are primarily regulated by the liver via hepatic
endogenous glucose production under the metabolic state with refrainment from eating for a
given period. The impaired fasting glucose in humans is defined as FBG > 100 mg/dl. In the
current study, mice underwent a morning fast for 5 hours starting at 7:30 am. The duration of
fasting is an important aspect of assessing metabolic abnormalities. Overnight fasting (12-18
hours) is reported to provide a steady-state FBG concentration, however, due to the high
metabolic rate of mice fasting for this long induces metabolic stress and significant weight loss
in the animals (10, 16). Five hours fast, on the other hand, reduce metabolic stress and is
equivalent to human physiology (3, 10). Overnight fasting has been suggested for evaluating
FBG in high-fat diet models to reduce variability. However, in the current study mice were kept
on a regular chow diet to evaluate physiological blood glucose regulation.
In an article from the Jackson laboratory (51) it has been reported that the normal range
of fasting blood glucose levels in mice is between 80 and 100 mg/dl after a 4 to 6 hour fast.
However, a variety of factors can influence the level of FBG baseline in each set of experiments.
FBG values that have been reported has a big range: 151.35±12.61 mg/dl in 18-week old
C57BL/6J mice after 4-hour fast (66), 96.2±10.2 mg/dl 12-hour daytime fast and 85.1±22.5
mg/dl 12 hour night time fast in male C57BL/6J (135), 141.98±4.32 mg/dl in 18- to 19-week old
male mice after a 6 hour fast (7), 124.33±7.2 mg/dl in 16-week old male C57BL/6 mice with an
unknown fasting time (53), 106.31±12.61 mg/dl in 12- to 16- week old 657BL/6 male mice after
a 4 hour fast (74). Given this information, fasting blood glucose levels may vary between studies
due to the mice (age, strain, littermate), fasting period, researchers (animal handling skills), and
experimental environment where the test is performed.
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In the current study, a pair of littermates, one wild type and one P2Y2R-/- mouse with the
same sex, were used for an experiment to evaluate FBG and IPGTT and minimize genetic
variance. The WT mice had 106±4.6 mg/dl FBG in males and 88.9±5.7 mg/dl in females (Fig. 9,
Table 5, Table 6). These data were consistently collected by one person in a consistent
environment with efforts to eliminate any stress by placing mice in a quiet area for fasting.
Further, the person handling the mice for each experiment and performing the experiments was
kept consistent in the current study, reducing stressors from different handlers between
experiments. In future studies, if multiple persons are performing experiments, it is necessary to
randomize experimental conditions, such alternating who is performing experiments on certain
cohorts of mice (123). In comparison to the FBG values reported from previous literature for
wild type mice, our fasting blood glucose levels in both females and males are consistent with
the values from literature reported above, despite differences in age, fasting time, and sex of the
mice. These data demonstrate that the data collected in the current study are consistent with
previously published literature and show the importance of maintaining consistency and reducing
stressors in metabolic studies (Fig. 9, Table 5, Table 6). Further, fasting blood glucose values for
P2Y2R-/- mice under physiological conditions have not been reported in literature yet. P2Y2R-/mice had 100.4±4.7 mg/dl in males and 95.1±4.5 mg/dl in females (Fig. 9, Table 5, Table 7). We
did not observe differences in FBG between wild type and P2Y2R-/- pairs in both males and
females, suggesting that P2Y2R does not alter FBG for either males or females.
Sex-specific differences in FBG have been observed in WT mice, but not found in
P2Y2R-/- mice. A significant difference was revealed in wild type mice with females displaying
lower FBG relative to males. As reported previously, women have lower FBG relative to male
counterparts. Contrarily, there is no sex-specific differences in FBG in P2Y2R-/- mice (Fig. 9,
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Table 7). The findings demonstrate that P2Y2R modulates sex-difference in FBG, suggesting that
P2Y2R regulates FBG in different manners between males and females. Given that FBG level is
primarily regulated by hepatic endogenous glucose production, our findings suggest that
contribution of P2Y2R to sex-specific differences in FBG under physiological conditions may be
through different responses of the liver to the fasting status between males and females. It is
worthy investigating hepatic glucose metabolism modulated by P2Y2R in males and females
with respect to its interaction with sex hormones regulating endogenous glucose production.

Assessment of P2Y2 Receptor Role During Glucose Tolerance Test
Glucose tolerance test are useful tools to monitor and detect changes in blood glucose in
response to an exogenous glucose load and allow for detection euglycemia or dysglycemia
(impaired glucose tolerance). In human, oral glucose tolerance test (OGTT) is used clinically as a
diagnostic tool for pre-diabetes, T2D, and gestational diabetes. In animal models, glucose
tolerance test allows researchers to characterize glucose metabolic phenotype in various disease
models under different conditions, such as sex, environment, treatments, and genetic
modifications. Exogeneous glucose can be administered through different routes, including oral
(OGTT), intravascular (IVGTT), or intraperitoneal (IPGTT) method, which subsequently
influences the levels of blood glucose because of different regulatory mechanisms. GTT results
may vary in how a glucose challenge is administered. OGTT is used in both humans and
animals, however, intravenous GTT (IVGTT) and intraperitoneal GTT (IPGTT) are often used in
animals.
GTT Assessment for Wild Type and P2Y2R-/- Male Littermates. Current literature
reported an important role of P2Y2R in high-fat diet induced obesity. The data collected from
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those studies show that P2Y2R contributes to insulin resistance and obesity under
pathophysiological conditions (93, 153) . In the current study under physiological conditions, we
observed higher blood glucose levels during glucose tolerance test in male P2Y2R-/- knockout
mice compared with WT mice, suggesting a novel protective effect of P2Y2R on maintaining
glucose tolerance in male mice (Fig. 10A, Table 8). Interestingly, in Zhang et al’s study using
regular diet, the male P2Y2R-/- mice had lower blood glucose levels over time of GTT relative to
wild type mice (153). However, they did not report any significant differences in GTT between
WT and P2Y2R-/- mice with normal diet. In addition, the genetic background for their mice is
B6D2 which is different from our mice (C57BL/6NJ), and the age of mice used for their study is
older than mice used in our study. We observed that P2Y2R-/- male mice increased blood glucose
levels starting at t = 20 relative to wild type mice (Fig. 10A). It is possible that aging-induced
decrease in insulin sensitivity could mask the effect of P2Y2R on the regulation of GTT. It is also
possible that differences in the genetic background of the mice could influence these differences
(107, 117, 131). In similar HFD experiments performed by Merz et al, mice with C57BL/6
background were used, the same background as our mice (93). However, data was only reported
for the HFD diet fed mice for GTT and ITT experiments. In conclusion our findings demonstrate
P2Y2R modulates physiological glucose tolerance in male mice with a C57BL/6 background
with age between 8 and 12 weeks old.
Impaired glucose tolerance and insulin resistance can result from dysfunction of
cardiovascular system (95, 99). Substantial data has shown P2Y2R regulates the homeostasis of
the cardiovascular system. For instance, hypertension is observed in both global P2Y2R-/- mice
and endothelial-specific knockout of P2Y2R mice (26, 118, 119, 147), implicating vasodilatory
effect of P2Y2R in endothelial cells. In our lab, we recently observed a similar phenomenon in
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P2Y2R’s role in leukocyte-endothelial interaction. Data shows that under physiological
conditions in vivo, P2Y2R-/- mice had increased leukocyte rolling and adhesion, hallmarks of
inflammation, relative to wild type controls, thus suggesting P2Y2R is important in maintaining
physiological leukocyte-endothelial interactions. Collectively with the current study, it is
suggested that P2Y2R is important in multiple organ systems in maintaining physiological
functions. It remains to study if P2Y2R-dependent glucose homeostasis is regulated through the
cardiovascular system.
GTT Assessment for Wild Type and P2Y2R-/- Female Littermates. Interestingly,
differences in glucose tolerance were not observed between female P2Y2R-/- and WT littermates
(Fig. 10B, Table 9). We do observe a trend, however, between t = 10 and t = 30 of increased
glucose concentration on the glucose response curve (Fig. 10B). This suggests several
possibilities. P2Y2R may not be necessary for regulating glucose tolerance in females.
Differences in insulin secretion from the pancreas may be occurring in compensatory response to
high blood glucose levels. Finally, increasing sample size in the female groups may allow us to
either reach a statistically significant difference or corroborate current findings.

Assessment of Sex-specific Difference During Glucose Tolerance Test
Sex differences in glucose homeostasis are well documented. Based on previous literature
in mice, we expected female mice to have lower blood glucose levels for GTT relative to male
mice. In the current study, sex differences in our wild type mice were as expected. We show that
female wild type mice have lower blood glucose levels over the course of the glucose tolerance
test, suggesting female WT mice have better glucose clearance than WT males (Fig. 11A, Table
10). This may be reflective of increased insulin sensitivity reported in both female mice and
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humans. Currently, sex-specific differences in the P2Y2R-/- animal model are not reported in
literature. Here, we characterized sex-specific differences in glucose tolerance in the P2Y2R-/model. Female P2Y2R-/- mice have lower blood glucose levels in GTT time course curve relative
to males were (Fig. 11B, Table 11). These data demonstrate that P2Y2R does not alter sexdifferences in glucose tolerance between female and male mice.
In mice, females can tolerate a glucose challenge better compared to male counterparts,
consistent with the data in both wild type and P2Y2R-/- mice in the current study. As discussed
earlier, this is not reflected in humans between men and women. During an oral glucose
tolerance test, women have higher blood glucose concentrations 2 hours after glucose challenge
compared with men. There are a few possibilities responsible for the discrepancy in GTT
between human and mice. As described previously, exogenous glucose is given to patients via
oral route vs. mice via intraperitoneal injection. Regulatory mechanisms of blood glucose
between oral and intraperitoneal routes differ, including decrease in blood glucose modulated by
incretins that are produced from the small intestine in response to ingested glucose. When
performing an OGTT with patients each patient is administered a standard amount of glucose, 75
g. However, in mice, the concentration of glucose was administered based upon body weight,
standardizing it for each experimental subject. Those factors may account for the inconsistency
in GTT sex difference between human and mice.

Study Limitations and Future Directions
It is imperative to assess insulin action to make more-solid conclusions from the data
collected in the current study. Due to the limitation of time and resources, this was not completed
in this thesis research. The mechanisms of P2Y2R modulating GTT in males and females
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remains to be investigated. In general, three possible ways to potentiate glucose tolerance by
P2Y2R in males include increase in: (1) blood insulin level; (2) insulin receptor sensitivity; (3)
insulin diffusion rate from blood to skeletal muscle or adipose tissue. Likewise, mechanisms of
sex differences in P2Y2R-mediated sex difference in FBG for WT mice as well as sexual
dimorphism in glucose tolerance for both wild type mice P2Y2R-/- remain to be studied. We
predict that sex difference in the regulation of blood glucose level by the liver is responsible for
distinctive FBG between males and females under fasting condition. Furthermore, the roles of
sex hormones, genes encoded on sex chromosomes, and epigenetic factors in the different
regulatory mechanisms between males and females are unclear. Further study on identifying
genes located on X or Y chromosome involved in sex-specific differences in regulation of blood
glucose level under various conditions is needed.
Standard protocol for working with the P2Y2 receptor is to challenge the receptor with
agonist UTP in comparison to basal activation. UTP challenge can be used to further elucidate if
receptor activation modulates glucose tolerance. This is a way to see if direct receptor activation
influences the conditions being evaluated. It is shown in hepatocyte and cultured skeletal muscle
cells that UTP activation stimulates P2Y2R and favors insulin resistance under hyperglycemic
conditions. In vivo activation of P2Y2R using UTP versus basal conditions during glucose
tolerance test in wild type mice in a combination with the findings from the current study may
allow us to comprehensively evaluate the role of P2Y2R in the regulation of blood glucose.
While UTP challenge in P2Y2R knock out mice also allows us to tease out the activation of other
P2Y receptors that are activated by UTP.
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